Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide, with a potentially serious prognosis. At present, management of IgAN is primarily based on therapeutic lifestyle changes, and excellent blood pressure control and maximized supportive treatment with the combination of inhibition of the renin-angiotensin-aldosterone system with either inhibitors of angiotensin-converting enzyme or angiotensin II receptor blockers and inhibitors of sodium-glucose cotransporter-2, and possibly in the future also with endothelin antagonists. Supportive care currently represents the cornerstone of treatment of IgAN. Targeted-release formulation of budesonide should replace systemic corticosteroids in patients with higher proteinuria and active histological lesions. New treatment options are aimed at immunopathogenesis of IgAN including depletion or modulation of Galactose-deficient-Immunoglobulin A1-producing B cells, plasma cells, and the alternate and/or lectin pathway of complement. The exact place of monoclonal antibodies and complement inhibitors will need to be determined. This article reviews potential supportive therapies currently available for patients with IgAN.

Department of Nephrology General University Hospital 1st Faculty of Medicine Prague Czech Republic

Department of Pharmacology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Zobrazit více v PubMed

Praga M, Gutiérrez E, González Eet al. . Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 2003;14:1578–83. 10.1097/01.ASN.0000068460.37369.DC PubMed DOI

Rauen T, Eitner F, Fitzner Cet al. . Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 2015;373:2225–36. 10.1056/NEJMoa1415463 PubMed DOI

Lv J, Zhang H, Wong MGet al. . Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 2017;318:432–42. 10.1001/jama.2017.9362 PubMed DOI PMC

KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 2021;100(4S):S1–276. PubMed

Rauen T, Wied S, Fitzner Cet al. . After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int 2020;98:1044–52. 10.1016/j.kint.2020.04.046 PubMed DOI

Maschio G, Alberti D, Locatelli Fet al. . Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. J Cardiovasc Pharmacol 1999;33 Suppl 1:S16–20; discussion S41-3. 10.1097/00005344-199900001-00004 PubMed DOI

Ruggenenti P, Perna A, Remuzzi G.. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol 2001;12:2832–7. 10.1681/ASN.V12122832 PubMed DOI

Li PK, Leung CB, Chow KMet al. . Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis 2006;47:751–60. 10.1053/j.ajkd.2006.01.017 PubMed DOI

Ohashi H, Oda H, Ohno Met al. . Losartan reduces proteinuria and preserves renal function in hypertensive patients with IgA nephropathy. Clin Exp Nephrol 2002;6:0224–8. 10.1007/s101570200038 DOI

Cheng J, Zhang X, Tian Jet al. . Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis. Int J Clin Pract 2012;66:917–23. 10.1111/j.1742-1241.2012.02970.x PubMed DOI

Lennartz DP, Seikrit C, Wied Set al. . Single versus dual blockade of the renin-angiotensin system in patients with IgA nephropathy. J Nephrol 2020;33:1231–9. 10.1007/s40620-020-00836-8 PubMed DOI PMC

Yusuf S, Teo KK, Pogue Jet al. . Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547–59. PubMed

Alshahrani S. Renin-angiotensin-aldosterone pathway modulators in chronic kidney disease: a comparative review. Front Pharmacol 2023;14:1101068. 10.3389/fphar.2023.1101068 PubMed DOI PMC

Cosimato C, Agoritsas T, Mavrakanas TA.. Mineralocorticoid receptor antagonists in patients with chronic kidney disease. Pharmacol Ther 2021;219:107701. 10.1016/j.pharmthera.2020.107701 PubMed DOI

Bolignano D, Palmer SC, Navaneethan SDet al. . Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 2014;4:Cd007004. PubMed

Bakris GL, Agarwal R, Anker SDet al. . Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020;383:2219–29. 10.1056/NEJMoa2025845 PubMed DOI

Agarwal R, Rossignol P, Romero Aet al. . Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2019;394:1540–50. 10.1016/S0140-6736(19)32135-X PubMed DOI

Heerspink HJL, Kosiborod M, Inzucchi SEet al. . Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 2018;94:26–39. 10.1016/j.kint.2017.12.027 PubMed DOI

McMurray JJV, Wheeler DC, Stefánsson BVet al. . Effects of dapagliflozin in patients with kidney disease, with and without heart failure. JACC Heart Fail 2021;9:807–20. 10.1016/j.jchf.2021.06.017 PubMed DOI

Jongs N, Greene T, Chertow GMet al. . Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 2021;9:755–66. 10.1016/S2213-8587(21)00243-6 PubMed DOI

Wheeler DC, Toto RD, Stefánsson BVet al. . A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 2021;100:215–24. 10.1016/j.kint.2021.03.033 PubMed DOI

Barratt J, Floege J.. SGLT-2 inhibition in IgA nephropathy: the new standard of care? Kidney Int 2021;100:24–6. 10.1016/j.kint.2021.04.002 PubMed DOI

Perkovic V, Jardine MJ, Neal Bet al. . Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295–306. 10.1056/NEJMoa1811744 PubMed DOI

McQuarrie EP, Gillis KA, Mark PB.. Seven suggestions for successful SGLT2i use in glomerular disease - a standalone CKD therapy? Curr Opin Nephrol Hypertens 2022;31:272–7. 10.1097/MNH.0000000000000786 PubMed DOI

Bjornstad P, Greasley PJ, Wheeler DCet al. . The potential roles of osmotic and nonosmotic sodium handling in mediating the effects of sodium-glucose cotransporter 2 inhibitors on heart failure. J Card Fail 2021;27:1447–55. 10.1016/j.cardfail.2021.07.003 PubMed DOI PMC

Jackson AM, Dewan P, Anand ISet al. . Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. Circulation 2020;142:1040–54. 10.1161/CIRCULATIONAHA.120.047077 PubMed DOI PMC

Bakris G, Oshima M, Mahaffey KWet al. . Effects of canagliflozin in patients with baseline eGFR <30 ml/min per 1.73 m2: subgroup analysis of the randomized CREDENCE trial. Clin J Am Soc Nephrol 2020;15:1705–14. PubMed PMC

Kasichayanula S, Liu X, Lacreta Fet al. . Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet 2014;53:17–27. 10.1007/s40262-013-0104-3 PubMed DOI

Staplin N, Roddick AJ, Emberson Jet al. . Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials. EClinicalMedicine 2021;41:101163. 10.1016/j.eclinm.2021.101163 PubMed DOI PMC

Coresh J, Heerspink HJL, Sang Yet al. . Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol 2019;7:115–27. 10.1016/S2213-8587(18)30313-9 PubMed DOI PMC

Parving HH, Brenner BM, McMurray JJet al. . Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204–13. 10.1056/NEJMoa1208799 PubMed DOI

Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 2022;400:1788–801. 10.1016/S0140-6736(22)02074-8 PubMed DOI PMC

Herrington WG, Staplin N, Wanner Cet al. . Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023;388:117–27. PubMed PMC

Chung EYM, Badve SV, Heerspink HJLet al. . Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond? Nephrology (Carlton) 2023;28:97–108. 10.1111/nep.14130 PubMed DOI PMC

Heerspink HJL, Radhakrishnan J, Alpers CEet al. . Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet 2023;401:1584–94. 10.1016/S0140-6736(23)00569-X PubMed DOI

Barratt J, Rovin B, Wong MGet al. . IgA nephropathy patient baseline characteristics in the Sparsentan PROTECT study. Kidney Int Rep 2023;8:1043–56. 10.1016/j.ekir.2023.02.1086 PubMed DOI PMC

2017 Annual Meeting American College of Clinical Pharmacology. Clin Pharmacol Drug Dev 2017;6 Suppl 1:3–72. PubMed

Heerspink HJL, Parving HH, Andress DLet al. . Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 2019;393:1937–47. 10.1016/S0140-6736(19)30772-X PubMed DOI

Dutta S, Samara E, Lam Wet al. . Multiple-dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist. Clin Drug Investig 2001;21:129–36. 10.2165/00044011-200121020-00005 PubMed DOI

Xiong H, Carr RA, Locke CSet al. . Dual effects of rifampin on the pharmacokinetics of atrasentan. J Clin Pharmacol 2007;47:423–9. 10.1177/0091270007299928 PubMed DOI

Dingemanse J, van Giersbergen PL.. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 2004;43:1089–115. 10.2165/00003088-200443150-00003 PubMed DOI

Dieterle W, Hengelage T.. Absolute bioavailability and pharmacokinetics of avosentan in man. Int J Clin Pharmacol Ther 2009;47:587–94. 10.5414/CPP47587 PubMed DOI

Zhang J, Lu X, Feng Jet al. . Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a systematic review and meta-analysis. Biomed Res Int 2021;2021:9171715. 10.1155/2021/9171715 PubMed DOI PMC

Bagchi S, Bhowmik D, Singh Get al. . Hydroxychloroquine reduces proteinuria in Indian patients with IgA nephropathy. Kidney Int Rep 2022;7:1443–4. 10.1016/j.ekir.2022.04.086 PubMed DOI PMC